AIM Vaccine(HKG:6660) wholly-owned subsidiary, AIM Rongyu (Ningbo) Biopharmaceutical, will submit an application for drug marketing registration after obtaining the production license for the iterative serum-free rabies vaccine, according to a Wednesday filing with the Hong Kong bourse.
The vaccine earlier underwent Phase III clinical trials and could meet the preset goals, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.